Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances

Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues

(2021) Jana Maria Nemmer et al.   Frontiers in Medicine

Chronic Prurigo: Similar Clinical Profile and Burden Across Clinical Phenotypes

(2021) Claudia Zeidler et al.   Frontiers in Medicine

Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate‐to‐severe atopic dermatitis*

(2021) J. Puelles et al.   BRITISH JOURNAL OF DERMATOLOGY

Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis

(2020) Hasina Maredia et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

(2020) Sonja Ständer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo

(2020) Andrea Chiricozzi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Prevalence of prurigo nodularis in the United States

(2020) Katherine A. Whang et al.   Journal of Allergy and Clinical Immunology-In Practice

The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non‐lesional skin

(2020) C. Zeidler et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response

(2020) Husein Husein-ElAhmed et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis

(2020) Kyle A. Williams et al.   Expert Review of Clinical Pharmacology

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial

(2019) Sonja Ständer et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Diagnostic and Treatment Algorithm for Chronic Nodular Prurigo

(2019) Hartmut F. Ständer et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

(2019) Jonathan I. Silverberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries

(2018) E. Brenaut et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY